These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2557 related items for PubMed ID: 29074098

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
    Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA, Kao S, Lin CC, Bauer TM, Clancy JS, Thurm H, Martini JF, Peltz G, Abbattista A, Li S, Ou SI.
    Lancet Oncol; 2019 Dec; 20(12):1691-1701. PubMed ID: 31669155
    [Abstract] [Full Text] [Related]

  • 3. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT.
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
    Lee J, Sun JM, Lee SH, Ahn JS, Park K, Choi Y, Ahn MJ.
    Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
    [Abstract] [Full Text] [Related]

  • 7. Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
    Seto T, Hayashi H, Satouchi M, Goto Y, Niho S, Nogami N, Hida T, Takahashi T, Sakakibara-Konishi J, Morise M, Nagasawa T, Suzuki M, Ohkura M, Fukuhara K, Thurm H, Peltz G, Nishio M.
    Cancer Sci; 2020 Oct; 111(10):3726-3738. PubMed ID: 32681682
    [Abstract] [Full Text] [Related]

  • 8. Clinical Management of Adverse Events Associated with Lorlatinib.
    Bauer TM, Felip E, Solomon BJ, Thurm H, Peltz G, Chioda MD, Shaw AT.
    Oncologist; 2019 Aug; 24(8):1103-1110. PubMed ID: 30890623
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F, Loriot Y, Kuo MS, Mahjoubi L, Lacroix L, Planchard D, Besse B, Farace F, Auger N, Remon J, Scoazec JY, André F, Soria JC, Friboulet L.
    Clin Cancer Res; 2016 Dec 15; 22(24):5983-5991. PubMed ID: 27401242
    [Abstract] [Full Text] [Related]

  • 13. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
    Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ, CROWN Trial Investigators.
    N Engl J Med; 2020 Nov 19; 383(21):2018-2029. PubMed ID: 33207094
    [Abstract] [Full Text] [Related]

  • 14. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.
    Seto T, Kiura K, Nishio M, Nakagawa K, Maemondo M, Inoue A, Hida T, Yamamoto N, Yoshioka H, Harada M, Ohe Y, Nogami N, Takeuchi K, Shimada T, Tanaka T, Tamura T.
    Lancet Oncol; 2013 Jun 19; 14(7):590-8. PubMed ID: 23639470
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.
    Soo RA, Huat Tan E, Hayashi H, Seto T, Lin CC, Ou SI, Kim DW, Liu G, Abbattista A, Martini JF, Hooi Wong C, Toffalorio F, Solomon BJ.
    Lung Cancer; 2022 Jul 19; 169():67-76. PubMed ID: 35660971
    [Abstract] [Full Text] [Related]

  • 18. First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib.
    Basit S, Ashraf Z, Lee K, Latif M.
    Eur J Med Chem; 2017 Jul 07; 134():348-356. PubMed ID: 28431340
    [Abstract] [Full Text] [Related]

  • 19. ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
    Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, Riely GJ, Ou SI, Clancy JS, Li S, Abbattista A, Thurm H, Satouchi M, Camidge DR, Kao S, Chiari R, Gadgeel SM, Felip E, Martini JF.
    J Clin Oncol; 2019 Jun 01; 37(16):1370-1379. PubMed ID: 30892989
    [Abstract] [Full Text] [Related]

  • 20. Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial.
    Shi Y, Fang J, Hao X, Zhang S, Liu Y, Wang L, Chen J, Hu Y, Hang X, Li J, Liu C, Zhang Y, Wang Z, Hu Y, Gu K, Huang J, Zhang L, Shan J, Ouyang W, Zhao Y, Zhuang W, Yu Y, Zhao J, Zhang H, Lu P, Li W, Si M, Ge M, Geng H.
    Signal Transduct Target Ther; 2022 Jan 28; 7(1):25. PubMed ID: 35087031
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 128.